50 mg bid (approx 12-hr intervals) on days 8-21 of induction & consolidation chemotherapy cycles & then bid as single agent maintenance for 12 mth. Patients w/ Grade 4 neutropenia (ANC <0.5 x 109/L)
Interrupt treatment until ANC ≥1 x 109
/L, then resume Rydapt at 50 mg bid. Advanced SM
Initially 100 mg bid. Treatment should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs. Patients w/ ANC <1 x 109/L who did not have severe neutropenia at baseline
Interrupt Rydapt until ANC ≥1.5 x 109
/L, then resume at 50 mg bid, & if tolerated, gradually increase to 100 mg bid. Patients w/ Grade 3/4 nausea &/or vomiting despite optimal anti-emetic therapy
Interrupt treatment for 3 days (6 doses), then resume Rydapt at 50 mg bid & if tolerated gradually increase to 100 mg bid.